Abstract:Abstract Precise and efficient image-guided immunotherapy holds great promise for cancer treatment. Here, we report a self-accelerated nanoplatform combining an aggregation-induced emission luminogen (AIEgen) and a hypoxia-responsive prodrug for multifunctional image-guided combination immunotherapy. The near-infrared AIEgen with methoxy substitution simultaneously possesses boosted fluorescence and photoacoustic (PA) brightness for the strong light absorption ability, as well as amplified type I and type II photodynamic therapy (PDT) properties via enhanced intersystem crossing process. By formulating the high-performance AIEgen with a hypoxia-responsive paclitaxel (PTX) prodrug into nanoparticles, and further camouflaging with macrophage cell membrane, a tumor-targeting theranostic agent is built. The integration of fluorescence and PA imaging helps to delineate tumor site sensitively, providing accurate guidance for tumor treatment. The light-induced PDT effect could consume the local oxygen and lead to severer hypoxia, accelerating the release of PTX drug. As a result, the combination of PDT and PTX chemotherapy induces immunogenic cancer cell death, which could not only elicit strong antitumor immunity to suppress the primary tumor, but also inhibit the growth of distant tumor in 4T1 tumor-bearing female mice. Here, we report a strategy to develop theranostic agents via rational molecular design for boosting antitumor immunotherapy.

What problem does this paper attempt to address?

The paper primarily aims to address the following key issues: 1. **The need for precise cancer treatment**: The research team aims to develop an efficient strategy for comprehensive diagnosis and treatment of diseases, particularly for precision medicine in cancer. However, existing technologies have some shortcomings. For example, while fluorescence imaging has high sensitivity, its tissue penetration ability is limited. On the other hand, photoacoustic imaging has better penetration depth and spatial resolution but relatively low sensitivity. 2. **Limitations of traditional cancer treatment methods**: Traditional cancer treatments such as surgery, chemotherapy, and radiotherapy often have limited anti-tumor effects due to tumor recurrence or metastasis. 3. **Challenges faced by immunotherapy**: Although immunotherapy shows great potential in changing the paradigm of cancer treatment, most solid tumors do not respond to immunotherapy due to low immunogenicity. These tumors are referred to as "cold tumors." To address the above issues, the research team designed a self-accelerating nano-platform that combines Aggregation-Induced Emission (AIE) materials and hypoxia-responsive prodrugs for multimodal imaging-guided combination immunotherapy. Specifically, the platform includes the following core components: - **AIEgen (AIE luminogen)**: The researchers designed a near-infrared AIEgen that not only has enhanced fluorescence and photoacoustic signals but also amplifies two types of photodynamic therapy (PDT) effects. This material achieves this goal through an enhanced intersystem crossing process. - **Hypoxia-responsive prodrug**: A hypoxia-responsive paclitaxel (PTX) prodrug is encapsulated with AIEgen into nanoparticles. When local oxygen is consumed by PDT, leading to more severe hypoxia, the release of the PTX drug can be accelerated. - **Macrophage membrane camouflage**: These nanoparticles are further camouflaged with M1 macrophage membranes to enhance their targeted accumulation at the tumor site. In summary, this platform aims to precisely locate tumors through the integration of fluorescence and photoacoustic imaging and to induce immunogenic cancer cell death through the synergistic effects of PDT and PTX chemotherapy. This not only inhibits the growth of primary tumors but also suppresses the growth of distant tumors, providing a new strategy to enhance the effectiveness of anti-tumor immunotherapy.

A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy